Technology

Invasive bacterial infections lead to morbidity and mortality, with infection control representing an increasing burden on the healthcare system and society

In the U.S. alone, healthcare associated bacterial infections result in > 100,000 deaths and costs of roughly $45 billion.
Specifically, S. aureus has become amongst the most common reasons for healthcare visits. S. aureus infections expenditure in the U.S. are estimated to be $15 billion.
The long-term use of antibiotics is not recommended by the Infectious Diseases Society of America (IDSA) for prevention of recurrent disease due to the increasing risk of developing antimicrobial resistance (AMR).

Centers For Disease Control and Prevention (CDC):

According to the CDC, 35,000 deaths per year in US are due to AMR.
Direct healthcare costs for AMR have reached $20 billion.

World Health Organization (WHO):

The WHO has declared antimicrobial resistance “one of the world’s most urgent threats”.

Not Just A New Treatment – A Fundamentally Novel Therapeutic Approach

Commense Bio is utilizing differentiated, cutting-edge biology to engineer optimized bacterial strains that physically occupy the skin microbiome to durably prevent undesired colonization. Our genetically-modified live biotherapeutics exert their mechanism of action through bacterial interference which involves the use of one bacterial species to prevent the growth of a second disease-causing bacterial.

Remove

Using standard protocol *, we remove disease-causing strains of colonizing bacteria (like Staph) from the patient.

Replace

Our modified bacteria are programmed to self-destruct below the skin surface.
CB-502 is not an antibiotic, avoiding the creation of anti-microbial resistance.